Anthony Bahinski, Global Head, Safety Pharmacology

Dr. Anthony Bahinski is Global Head of Safety Pharmacology at GlaxoSmithKline. Prior to joining GlaxoSmithKline, he was a member of the Advanced Technology Team at the Wyss Institute for Biologically Inspired Engineering at Harvard University where he led development of novel Organ-on-a-Chip technologies for more predictive in vitro assays for safety and efficacy of drugs, vaccines and biologics. Dr. Bahinski’s career spans academic research and large Pharma, with over 19 years’ experience in the pharmaceutical industry (including P&G, Pharmacia, Pfizer). Dr. Bahinski received his PhD in Physiology from Temple University, Philadelphia, PA and his MBA from Xavier University, Cincinnati, OH. He completed post docs at Rockefeller University and the University of Cincinnati. Dr. Bahinski has served on several advisory boards and is a current member of the Science Board of the United States Food and Drug Administration, the EPA’s Board of Scientific Counselors (BOSC), member of EU H2020 ORgan-on-Chip In Development (ORCHID) Advisory Board and former member of the Board of Directors of the Safety Pharmacology Society. He is a member of the Editorial Board of the journals, Applied In Vitro Toxicology and Frontiers in Pharmacology of Ion Channels and Channelopathies. He has served on Peer Review Panels at the NIH, EPA and NCI SBIR. He has served the Society of Toxicology as Councilor (Executive Committee) of the Drug Discovery Toxicology Specialty Section and is current Vice President-Elect of the Cardiovascular Toxicology Specialty Section. He is author/co-author of 42 publications including peer-reviewed articles and book chapters.